Evidence map›Paper›PMID 39550107›Full record

ReviewRheumatic diseases clinics of North America2025

Interventions to Improve COVID-19 Vaccine Hesitancy.

Nnenna Ezeh, Taussia Boadi, Maria I Danila, Rosalind Ramsey-Goldman, Candace H Feldman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatic diseases clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nnenna EzehDepartment of Medicine, Harvard Combined Dermatology Residency; Department of Dermatology, Harvard Combined Dermatology Residency; Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Taussia BoadiDivision of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115, USA.
Maria I DanilaDivision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL 35294, USA.
Rosalind Ramsey-GoldmanDivision of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 633 North St. Clair, 18th Floor, Chicago, IL 60611, USA.
Candace H FeldmanDivision of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: cfeldman@bwh.harvard.edu.

Funding

Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015AOT2HL161841 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FOULKES, ANDREA S, KARLSON, ELIZABETH W · 2021 to 2024
$182.2M
The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TERKELTAUB, ROBERT A. · 2012 to 2021
$12.8M
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Resource CoreP30AR072579 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Leena Sharma · 2017 to 2026
$8.3M
The Roybal Center for TherapeuticOptimization using BehavioralScienceP30AG064199 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Julie Christine Lauffenburger · 2019 to 2026
$8.3M
Optimizing the value of pain management in knee OA patients with comorbiditiesR01AR074290 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Elena Losina · 2018 to 2026
$5.9M
Methods and Health Informatics CoreP30AR072583 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JEFFREY R. CURTIS · 2020 to 2026
$5.7M
Psychosocial Factors and Lupus Disease Progression Among African American WomenR01AR065493 · NIAMS · UNIV OF MARYLAND, COLLEGE PARK · PI CHAE, H. DAVID, LIM, SUNG SAM · 2014 to 2022
$4.2M
The Relationship Between Brain Macrophages and Cognitive Dysfunction in Systemic Lupus ErythematosusR01AI170938 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Carla M Cuda · 2022 to 2026
$3.9M
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signalsR01AI153365 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LUND, FRANCES E. · 2020 to 2024
$3.6M
Improving COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Groupswith Rheumatic DiseasesR01MD019235 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Maria Ioana Danila · 2023 to 2026
$3.1M
Lupus Intervention Fatigue Trial (LIFT)R01AR071091 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI EHRLICH-JONES, LINDA S., RAMSEY-GOLDMAN, ROSALIND · 2018 to 2022
$3.0M
Department of Defense W81XWWH2010692NHLBI NIH HHS OT2 HL161841NIAID NIH HHS R01 AI153365NIAID NIH HHS R01 AI170938NIAID NIH HHS R21 AI171491NIAMS NIH HHS P30 AR072577NIAMS NIH HHS P30 AR072579NIAMS NIH HHS P30 AR072583NIAMS NIH HHS P50 AR060772NIAMS NIH HHS R01 AR065493NIAMS NIH HHS R01 AR071091NIAMS NIH HHS R01 AR074290NIAMS NIH HHS R01 AR080089NIAMS NIH HHS R03 AR083661NIA NIH HHS P30 AG064199NIMHD NIH HHS R01 MD019235
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) vaccine uptake among individuals with rheumatic conditions remains low despite heightened risk for related adverse outcomes. This is especially pronounced among historically marginalized populations who suffered disproportionately from the COVID-19 pandemic. Among the myriad of reasons for low vaccine uptake, mistrust in the healthcare system, misinformation related to the vaccine development process, fear of rheumatic disease flares, and inconsistent physician recommendations, are highlighted. Two randomized controlled trials are underway leveraging multimodal strategies and community partnerships to disseminate COVID-19 vaccine information, reduce hesitancy and hopefully improve vaccine uptake, particularly in marginalized communities.

Indexed as

COVID-19COVID-19 VaccinesVaccination HesitancyHumansPatient Acceptance of Health CareRheumatic DiseasesSARS-CoV-2COVID-19 VaccinesCoronavirus disease 2019 infectionCoronavirus disease 2019 vaccinationHealth disparitiesPreventive careVaccine hesitancy

Identifiers

PMID39550107
PMCPMC11569381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.